Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT6S2FE)

• DTT Name: DNA [cytosine-5]-methyltransferase 1 (DNMT1) DTT Info
• Gene Name: DNMT1

Molecule-Related Drug & Molecule List

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CC-486	DMTNQB0	Acute myeloid leukaemia	2A60	Phase 3	[1]
Guadecitabine	DM9Y3EG	Myelodysplastic syndrome	2A37	Phase 3	[2]
S-110	DMXY34J	Acute myeloid leukaemia	2A60	Phase 3	[3]
SGI110	DM1NQDW	Acute myeloid leukaemia	2A60	Phase 3	[4]
Antroquinonol	DMRGQVZ	Non-small-cell lung cancer	2C25.Y	Phase 2	[5]
Palifosfamide	DMMIYZ7	Soft tissue sarcoma	2B57	Phase 2	[6]
RX-3117	DME8ARP	Bladder cancer	2C94	Phase 2	[7]
GSK4172239	DM930LE	Sickle-cell disorder	3A51	Phase 1	[8]

16 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27376512-Compound-asCEBP-1	DMTQRVC	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-asCEBP-1HPE	DMLAY8B	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-asCEBP-2	DMJUL1A	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-asCEBP-2HPE	DM9QEIV	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-miR-155-5p	DM67VNW	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-MTC-422	DM1MVQD	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-MTC-423	DM9RSDX	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-MTC-424	DMGNRZU	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-MTC-427	DMWXEZD	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-MTC-433	DM7OS5E	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-Table1Example11	DMIFTUN	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-Table1Example16	DMM3VA8	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-Table1Example30	DM5RX9D	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-Table1Example4	DMFJG7P	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-Table1Example5	DM4Q6XZ	N. A.	N. A.	Patented	[9]
PMID27376512-Compound-Table1Example8	DMKU7GD	N. A.	N. A.	Patented	[9]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CP-4200	DMZMKAQ	Solid tumour/cancer	2A00-2F9Z	Investigative	[10]
PMX-700	DMZCSF1	Glioblastoma multiforme	2A00.0	Investigative	[10]
XB-05	DMYT5DI	Solid tumour/cancer	2A00-2F9Z	Investigative	[10]

References

• [1] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
• [4] Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
• [5] Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
• [6] Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
• [7] Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
• [8] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [9] DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605).